Evidence map›Paper›PMID 24987168›Full record

ReviewIndian journal of pharmacology

Social pharmacology: expanding horizons.

Rituparna Maiti, José Luis Alloza

Abstract readReview
In one paragraph

Review in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Number-Based Approach to Insulin Taxonomy.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2015
    Article
  3. Social pharmacology and diabetes.Indian journal of pharmacology
    Article
  4. Timely insulin use: Need for social marketing.Indian journal of endocrinology and metabolism
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Rituparna MaitiDepartment of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
José Luis AllozaDepartment of Biomedical Sciences, School of Medicine and Health Sciences, The University of Alcalá, E 28771 Alcalá de Henares, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current modern and global society, social changes are in constant evolution due to scientific progress (technology, culture, customs, and hygiene) and produce the freedom in individuals to take decisions by themselves or with their doctors toward drug consumption. In the arena of marketed drug products which includes society, individual, administration, and pharmaceutical industry, the young discipline emerged is social pharmacology or sociopharmacology. This science arises from clinical pharmacology, and deals with different parameters, which are important in creating knowledge on marketed drugs. However, the scope of "social pharmacology" is not covered by the so-called "Phase IV" alone, but it is the science that handles the postmarketing knowledge of drugs. The social pharmacology studies the "life cycle" of any marketed pharmaceutical product in the social terrain, and evaluates the effects of the real environment under circumstances totally different in the drug development process. Therefore, there are far-reaching horizons, plural, and shared predictions among health professionals and other, for beneficial use of a drug, toward maximizing the benefits of therapy, while minimizing negative social consequences.

Indexed as

Pharmacology, ClinicalCultureHumansProduct Surveillance, PostmarketingSociological FactorsClinical pharmacologydrug abusePhase IVpost marketing periodsociopharmacology

Identifiers

PMID24987168
PMCPMC4071698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.